GPU compute just became the new real estate. This week's headline raise belongs to GMI Cloud, which pulled in a staggering $668 million in combined equity and debt to build out AI inference infrastructure across the US and Asia-Pacific.
The headline raise: GMI Cloud, $668M
What they do: GMI Cloud operates an AI-native GPU cloud platform built to deliver compute, inference, and agent infrastructure at scale. Think of it as the picks-and-shovels play for the agentic AI wave, letting enterprises deploy production AI across single inference nodes to multi-region AI factories.
The numbers: $223M in Series B equity led by ARCHIV, plus a $445M credit facility from CTBC. Backers include NVIDIA, DSC Investment, Trend Micro, KB Investment, Kyobo Life, and KT Corporation.
HQ: Mountain View, California (with expansion planned across the US, Taiwan, and broader APAC).
Valuation: Not disclosed, but the combined raise signals a company operating well north of unicorn territory.
How they announced it
GMI Cloud played the classic enterprise infrastructure playbook: let the investor roster do the talking. Having NVIDIA on the cap table is not just capital, it is a signal to every enterprise buyer that the compute you are renting is blessed by the people who make the chips. The announcement dropped midweek, timed to land while enterprise procurement teams were still reading their inboxes rather than winding down for the weekend.
The company leaned heavily on the credit facility as proof of bankability. Combining a $223M equity raise with a $445M debt facility from CTBC sends a specific message: "We have revenue, we have assets, and the banks agree." That framing matters in a sector where many GPU cloud startups are still burning through runway.
No founder-first content push was visible. No podcast tour. No LinkedIn essay. This was a deal that spoke through its structure rather than its story.
Actionable insights
Lead with your investor signal, not your pitch deck. GMI Cloud let the NVIDIA name carry weight. If you have a strategic backer whose brand validates your product, make their involvement the headline rather than burying it in paragraph three.
Pair equity with debt to reframe the conversation. A $223M equity raise is impressive. A $668M combined raise changes the category. If your business model supports asset-backed lending, structuring a debt facility alongside your equity round makes you look like infrastructure rather than a startup.
Time your announcement for buyer attention, not media cycles. Midweek drops work for enterprise B2B because the people who sign purchase orders are at their desks. Consumer startups might chase the Monday morning TechCrunch slot, but infrastructure plays benefit from Tuesday-Wednesday visibility.
Other notable US rounds this week
PaleBlueDot AI raised $200M in Series C at a $3.2B valuation for its intelligence infrastructure platform, led by ComputeCore with B Capital participating. Another GPU/compute play hitting scale.
NorthStar Medical Technologies secured up to $185M in growth financing from Hercules Capital to accelerate production of actinium-225 for precision cancer therapies. Radiopharmaceuticals continue attracting serious capital.
NexBank Capital raised $150M through non-voting common stock, bringing total capital to $540M. An $18B-asset financial holding company scaling its institutional banking platform.
Reco picked up $55M from AT&T Ventures, Forestay, and Quadrille Capital for its agentic security platform. Total funding now $140M, covering 280+ app integrations including OpenAI, Anthropic, and Microsoft Copilot.
Flow Engineering closed $50M in Series B at a $750M valuation for its agentic hardware development platform, co-led by Antonio Gracias and Gavin Baker with Sequoia Capital participating. Bringing AI agents to physical product engineering.
Fortem Technologies raised $50M in Series B led by Lockheed Martin for its AI-powered drone defence and airspace security platform. Defence tech continues its march.
ai3Bio secured $48M in Series A led by UPMC Enterprises and Ziff Capital Partners for biotech targeting autoimmune disease through direct Th17 cell elimination.
The theme this week is clear: compute infrastructure and security are absorbing the largest cheques, while biotech and defence tech maintain consistent dealflow at the $50M+ level.
